PEDIATRIX MEDICAL GROUP INC (MD) Fundamental Analysis & Valuation
NYSE:MD • US58502B1061
Current stock price
21.525 USD
+0.34 (+1.63%)
Last:
This MD fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. MD Profitability Analysis
1.1 Basic Checks
- MD had positive earnings in the past year.
- In the past year MD had a positive cash flow from operations.
- The reported net income has been mixed in the past 5 years: MD reported negative net income in multiple years.
- MD had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- With an excellent Return On Assets value of 7.36%, MD belongs to the best of the industry, outperforming 87.00% of the companies in the same industry.
- MD has a better Return On Equity (19.10%) than 86.00% of its industry peers.
- With a decent Return On Invested Capital value of 9.88%, MD is doing good in the industry, outperforming 80.00% of the companies in the same industry.
- The Average Return On Invested Capital over the past 3 years for MD is in line with the industry average of 8.63%.
- The last Return On Invested Capital (9.88%) for MD is above the 3 year average (8.21%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.36% | ||
| ROE | 19.1% | ||
| ROIC | 9.88% |
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
1.3 Margins
- MD has a better Profit Margin (8.64%) than 91.00% of its industry peers.
- MD's Profit Margin has improved in the last couple of years.
- MD's Operating Margin of 12.07% is amongst the best of the industry. MD outperforms 84.00% of its industry peers.
- MD's Operating Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 12.07% | ||
| PM (TTM) | 8.64% | ||
| GM | N/A |
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. MD Health Analysis
2.1 Basic Checks
- MD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
- Compared to 1 year ago, MD has less shares outstanding
- Compared to 5 years ago, MD has less shares outstanding
- Compared to 1 year ago, MD has an improved debt to assets ratio.
2.2 Solvency
- MD has an Altman-Z score of 2.07. This is not the best score and indicates that MD is in the grey zone with still only limited risk for bankruptcy at the moment.
- MD has a Altman-Z score (2.07) which is in line with its industry peers.
- The Debt to FCF ratio of MD is 2.36, which is a good value as it means it would take MD, 2.36 years of fcf income to pay off all of its debts.
- MD has a better Debt to FCF ratio (2.36) than 74.00% of its industry peers.
- A Debt/Equity ratio of 0.66 indicates that MD is somewhat dependend on debt financing.
- MD's Debt to Equity ratio of 0.66 is in line compared to the rest of the industry. MD outperforms 55.00% of its industry peers.
- Even though the debt/equity ratio score it not favorable for MD, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 2.36 | ||
| Altman-Z | 2.07 |
ROIC/WACC1.18
WACC8.39%
2.3 Liquidity
- A Current Ratio of 1.66 indicates that MD should not have too much problems paying its short term obligations.
- The Current ratio of MD (1.66) is better than 69.00% of its industry peers.
- MD has a Quick Ratio of 1.66. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
- MD has a better Quick ratio (1.66) than 70.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.66 |
3. MD Growth Analysis
3.1 Past
- MD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.24%, which is quite impressive.
- Measured over the past years, MD shows a quite strong growth in Earnings Per Share. The EPS has been growing by 10.01% on average per year.
- MD shows a decrease in Revenue. In the last year, the revenue decreased by -4.92%.
- Measured over the past years, MD shows a small growth in Revenue. The Revenue has been growing by 1.99% on average per year.
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%
3.2 Future
- Based on estimates for the next years, MD will show a small growth in Earnings Per Share. The EPS will grow by 0.99% on average per year.
- Based on estimates for the next years, MD will show a small growth in Revenue. The Revenue will grow by 3.93% on average per year.
EPS Next Y13.36%
EPS Next 2Y8.67%
EPS Next 3Y4.87%
EPS Next 5Y0.99%
Revenue Next Year1.07%
Revenue Next 2Y1.84%
Revenue Next 3Y2.77%
Revenue Next 5Y3.93%
3.3 Evolution
- The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. MD Valuation Analysis
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 10.60 indicates a reasonable valuation of MD.
- Based on the Price/Earnings ratio, MD is valued cheaper than 91.00% of the companies in the same industry.
- MD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.17.
- MD is valuated reasonably with a Price/Forward Earnings ratio of 9.35.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of MD indicates a rather cheap valuation: MD is cheaper than 93.00% of the companies listed in the same industry.
- When comparing the Price/Forward Earnings ratio of MD to the average of the S&P500 Index (23.05), we can say MD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.6 | ||
| Fwd PE | 9.35 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, MD is valued cheaper than 88.00% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of MD indicates a rather cheap valuation: MD is cheaper than 90.00% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.07 | ||
| EV/EBITDA | 6.84 |
4.3 Compensation for Growth
- MD's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- MD has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)0.79
PEG (5Y)1.06
EPS Next 2Y8.67%
EPS Next 3Y4.87%
5. MD Dividend Analysis
5.1 Amount
- MD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
MD Fundamentals: All Metrics, Ratios and Statistics
NYSE:MD (4/6/2026, 2:44:31 PM)
21.525
+0.34 (+1.63%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)02-19 2026-02-19/bmo
Earnings (Next)04-30 2026-04-30/bmo
Inst Owners102.64%
Inst Owner Change0%
Ins Owners1.94%
Ins Owner Change-0.8%
Market Cap1.79B
Revenue(TTM)1.91B
Net Income(TTM)165.39M
Analysts78.67
Price Target21.76 (1.09%)
Short Float %3.74%
Short Ratio3.47
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.87%
Min EPS beat(2)-9.94%
Max EPS beat(2)39.68%
EPS beat(4)3
Avg EPS beat(4)20.9%
Min EPS beat(4)-9.94%
Max EPS beat(4)39.68%
EPS beat(8)7
Avg EPS beat(8)17.99%
EPS beat(12)7
Avg EPS beat(12)8.59%
EPS beat(16)8
Avg EPS beat(16)5.12%
Revenue beat(2)1
Avg Revenue beat(2)-0.49%
Min Revenue beat(2)-1.41%
Max Revenue beat(2)0.42%
Revenue beat(4)1
Avg Revenue beat(4)-1.1%
Min Revenue beat(4)-1.97%
Max Revenue beat(4)0.42%
Revenue beat(8)2
Avg Revenue beat(8)-1.43%
Revenue beat(12)2
Avg Revenue beat(12)-2.28%
Revenue beat(16)2
Avg Revenue beat(16)-2.52%
PT rev (1m)-0.78%
PT rev (3m)-5.88%
EPS NQ rev (1m)-0.75%
EPS NQ rev (3m)-1.3%
EPS NY rev (1m)2.14%
EPS NY rev (3m)2.14%
Revenue NQ rev (1m)-0.28%
Revenue NQ rev (3m)-1.72%
Revenue NY rev (1m)-1.59%
Revenue NY rev (3m)-1.59%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 10.6 | ||
| Fwd PE | 9.35 | ||
| P/S | 0.93 | ||
| P/FCF | 7.07 | ||
| P/OCF | 6.59 | ||
| P/B | 2.06 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.84 |
EPS(TTM)2.03
EY9.43%
EPS(NY)2.3
Fwd EY10.69%
FCF(TTM)3.04
FCFY14.14%
OCF(TTM)3.27
OCFY15.17%
SpS23.06
BVpS10.43
TBVpS-4.96
PEG (NY)0.79
PEG (5Y)1.06
Graham Number21.83
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.36% | ||
| ROE | 19.1% | ||
| ROCE | 12.93% | ||
| ROIC | 9.88% | ||
| ROICexc | 13.71% | ||
| ROICexgc | 1686.9% | ||
| OM | 12.07% | ||
| PM (TTM) | 8.64% | ||
| GM | N/A | ||
| FCFM | 13.2% |
ROA(3y)0.01%
ROA(5y)1.53%
ROE(3y)-0.32%
ROE(5y)4.22%
ROIC(3y)8.21%
ROIC(5y)7.97%
ROICexc(3y)10.42%
ROICexc(5y)9.77%
ROICexgc(3y)618.91%
ROICexgc(5y)394.62%
ROCE(3y)10.75%
ROCE(5y)10.43%
ROICexgc growth 3Y208.98%
ROICexgc growth 5Y85.34%
ROICexc growth 3Y17.7%
ROICexc growth 5Y11.82%
OM growth 3Y5.99%
OM growth 5Y4.02%
PM growth 3Y36.96%
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score8
Asset Turnover0.85
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.66 | ||
| Debt/FCF | 2.36 | ||
| Debt/EBITDA | 2.26 | ||
| Cap/Depr | 84.57% | ||
| Cap/Sales | 0.96% | ||
| Interest Coverage | 6.72 | ||
| Cash Conversion | 107.19% | ||
| Profit Quality | 152.75% | ||
| Current Ratio | 1.66 | ||
| Quick Ratio | 1.66 | ||
| Altman-Z | 2.07 |
F-Score8
WACC8.39%
ROIC/WACC1.18
Cap/Depr(3y)81.68%
Cap/Depr(5y)85.74%
Cap/Sales(3y)1.24%
Cap/Sales(5y)1.38%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.24%
EPS 3Y6.72%
EPS 5Y10.01%
EPS Q2Q%-1.96%
EPS Next Y13.36%
EPS Next 2Y8.67%
EPS Next 3Y4.87%
EPS Next 5Y0.99%
Revenue 1Y (TTM)-4.92%
Revenue growth 3Y-0.99%
Revenue growth 5Y1.99%
Sales Q2Q%-1.71%
Revenue Next Year1.07%
Revenue Next 2Y1.84%
Revenue Next 3Y2.77%
Revenue Next 5Y3.93%
EBIT growth 1Y25.81%
EBIT growth 3Y4.93%
EBIT growth 5Y6.1%
EBIT Next Year16.33%
EBIT Next 3Y6.84%
EBIT Next 5YN/A
FCF growth 1Y36.89%
FCF growth 3Y22.56%
FCF growth 5Y7.52%
OCF growth 1Y31.23%
OCF growth 3Y17.54%
OCF growth 5Y5.79%
PEDIATRIX MEDICAL GROUP INC / MD Fundamental Analysis FAQ
What is the ChartMill fundamental rating of PEDIATRIX MEDICAL GROUP INC (MD) stock?
ChartMill assigns a fundamental rating of 6 / 10 to MD.
Can you provide the valuation status for PEDIATRIX MEDICAL GROUP INC?
ChartMill assigns a valuation rating of 8 / 10 to PEDIATRIX MEDICAL GROUP INC (MD). This can be considered as Undervalued.
Can you provide the profitability details for PEDIATRIX MEDICAL GROUP INC?
PEDIATRIX MEDICAL GROUP INC (MD) has a profitability rating of 7 / 10.
Can you provide the financial health for MD stock?
The financial health rating of PEDIATRIX MEDICAL GROUP INC (MD) is 6 / 10.